Sangamo BioSciences

Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins for the development of novel therapeutic strategies for unmet medical needs. We are worldwide leaders in the development of a proprietary technology platform that enables specific regulation of gene expression and gene modification. The basis of this platform is a naturally occurring class of transcription factors, zinc finger DNA-binding proteins (ZFPs) which we can engineer to drive desired therapeutic outcomes. Engineered ZFPs can be linked to functional domains that normally activate or repress gene expression to create ZFP transcription factors (ZFP TFs) capable of turning genes on or off. We can also link ZFPs to nuclease domains to create zinc finger nucleases (ZFNs) which enable precise gene-editing in cells. Engineered ZFNs can modify a cell's DNA at a precise location, thereby facilitating correction or disruption of a specific gene or the targeted addition of a new DNA sequence. Our primary mission is to develop ZFP Therapeutics®. We have ongoing clinical programs to evaluate ZFP TFs and ZFNs as novel approaches to unmet medical needs where we believe we have a differential technical advantage to impact the outcome of disease by functioning at the DNA level.
Company Growth (employees)
Richmond, US
Size (employees)
131 (est)
Sangamo BioSciences was founded in 1995 and is headquartered in Richmond, US

Key People at Sangamo BioSciences

Edward Lanphier

Edward Lanphier

President and CEO

Sangamo BioSciences Office Locations

Sangamo BioSciences has an office in Richmond
Richmond, US (HQ)
501 Canal Blvd

Sangamo BioSciences Data and Metrics

Sangamo BioSciences Financial Metrics

Sangamo BioSciences's revenue was reported to be $3.4 m in Q1, 2017

Revenue (Q1, 2017)

3.4 m

Net income (Q1, 2017)

(16.6 m)

EBIT (Q1, 2017)

(16.8 m)

Market capitalization (15-Sep-2017)

1 b

Cash (31-Mar-2017)

18.5 m
Sangamo BioSciences's current market capitalization is $1 b.
USDFY, 2013Y, 2014Y, 2015FY, 2016


24.1 m45.9 m39.5 m19.4 m

Revenue growth, %


R&D expense

65.6 m

General and administrative expense

26.3 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


10.4 m12.4 m13.5 m8.4 m8.6 m3.9 m3.7 m2.8 m3.4 m

R&D expense

13.4 m16.3 m15 m15.6 m16.7 m15.3 m19.5 m17 m12.9 m

General and administrative expense

4 m3.7 m4.7 m5 m4.6 m5.4 m11.1 m5 m7.3 m

Operating expense total

17.4 m20 m19.7 m20.6 m21.3 m20.6 m30.5 m22 m20.2 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


10.2 m6 m69.5 m22.1 m

Accounts Receivable

3.2 m10.4 m2.5 m5 m

Current Assets

97.3 m190.9 m212.6 m149.6 m


1.4 m1.5 m2.9 m6.6 m
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017


99.3 m11.2 m25.3 m10.8 m34.3 m33 m13 m28 m18.5 m

Accounts Receivable

7 m8.5 m6.6 m5.2 m7 m2.6 m2.3 m1.5 m2.4 m

Current Assets

203 m173.2 m203.9 m221 m227.7 m191.1 m176.2 m148.8 m133.8 m


1.6 m1.6 m3 m3.2 m3.1 m3.2 m3 m4.9 m7.3 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(26.6 m)(26.4 m)(40.7 m)(71.7 m)

Depreciation and Amortization

569 k549 k988 k997 k

Accounts Receivable

1 m(7.2 m)7.8 m(2.1 m)

Cash From Operating Activities

(19.5 m)(5.7 m)(33.7 m)(65.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(7 m)(7.5 m)(5.3 m)(12.1 m)(9.2 m)(16.5 m)(26.6 m)(19 m)(16.6 m)

Accounts Receivable

7 m8.5 m6.6 m5.2 m7 m2.6 m2.3 m1.5 m2.4 m
USDY, 2017


26.1 k

Financial Leverage

1.2 x
Show all financial metrics

Sangamo BioSciences Market Value History

Traffic Overview of Sangamo BioSciences

Sangamo BioSciences Company Life and Culture

You may also be interested in